Tolerability and comparative effectiveness of TNF-, IL-17-, and IL-23(p19) inhibitors in psoriatic arthritis: A target trial emulation study.

Zara R Stisen,Sabrina M Nielsen,Marie Skougaard,Mette Mogensen,Tanja Schjødt Jørgensen,Lene Dreyer,Maarten de Wit,Robin Christensen,Lars Erik Kristensen

Rheumatology (Oxford, England)（2023）

引用 0|浏览14

暂无评分

摘要

No decisive differences between drugs were observed at group level regarding drug survival and clinical outcomes after 12 months. TNFi, IL-17i, and IL-23(p19)i may all be considered equally effective in the treatment of patients with PsA, advocating for investigating more in personalised treatment strategies.

查看译文

关键词

psoriatic arthritis, biological therapy, drug survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要